Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome

NCT01459159 is registered in ClinicalTrials.gov with Telik as lead sponsor.

NCT NCT01459159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01459159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2b Study of Oral Ezatiostat Hydrochloride (Telintra®) in Patients With Low to Intermediate-1 Risk, Non-Deletion 5q Myelodysplastic Syndrome
Lead sponsor
Telik
Phase
Phase 2
Overall status
Terminated
Start date
October 31, 2011
Completion date
February 28, 2013
Enrollment
162 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome (mds)